Process Development

Phase Appropriate by Design: Why It Matters

How early decisions reduce downstream risk and support smoother technology transfer.
  • 1 min read
  • BY APS PHARMA SCIENTIFIC TEAM
SHARE ARTICLE

How early decisions reduce downstream risk and support smoother technology transfer.

About the Author

APS Pharma Scientific Team

Process Development & CMC Experts

Our scientists bring practical experience in pharmaceutical process development, analytical science and CMC strategy.

Explore Topics

Process Development

Lipid Science

Analytical Chemistry

CMC Strategy

Technology Transfer

Regulatory & Quality

Related Insights

Phase Appropriate by Design:Building Better Processes, Step by Step

Managing Impurities Through the Process

Direct Access. Deep Expertise.

Polymorph Screening: More Than Just Finding a Form

Stay Informed

Receive new APS Pharma insights on complex chemistry, development and scale-up.

Latest from APS

  • Process Development

Phase Appropriate by Design:Building Better Processes, Step by Step

Aligning development activities with program phase reduces risk, focuses resources and accelerates the path to commercialization.
READ MORE
  • CMC & Scale-up

Managing Impurities Through the Process

Understanding impurity fate and purge for safer, more efficient development.
READ MORE

Have a Challenging Molecule or Process?

Talk directly with an APS scientist about your chemistry, scale-up or development challenge.

DISCUSS A PROJECT
SUBMIT AN RFP